A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’

Nabiximols is a therapeutic option for patients with multiple sclerosis (MS) spasticity whose symptoms are poorly controlled by conventional oral first‐line medications. This study aimed to assess the relationship between changes in spasticity severity (measured on the 0–10 numeric rating scale [NRS]) and the presence of associated symptoms in patients treated with nabiximols, and to investigate the presence of the newly described ‘spasticity‐plus syndrome’.

• Publication year

  2022

• Venue

  European Journal of Neurology

• Publication date

  2022-05-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ene.15412PMID 35590453PMCID 9539865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’

  2022cited by this paper
• Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology

  2021cited by this paper
• Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

  2021cited by this paper
• Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study

  2021cited by this paper
• Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study

  2020cited by this paper
• Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study

  2020cited by this paper
• The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms

  2020cited by this paper
• EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis

  2020cited by this paper
• Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study

  2020cited by this paper
• EAN guideline on palliative care of people with severe, progressive multiple sclerosis

  2020cited by this paper
• Italian consensus on treatment of spasticity in multiple sclerosis

  2019cited by this paper
• The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)

  2019cited by this paper
• The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?

  2018cited by this paper
• Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

  2018cited by this paper
• Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)

  2017cited by this paper
• Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

  2016cited by this paper
• Long‐Term Data of Efficacy, Safety, and Tolerability in a Real‐Life Setting of THC/CBD Oromucosal Spray‐Treated Multiple Sclerosis Patients

  2016cited by this paper
• Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

  2016cited by this paper
• Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice

  2016cited by this paper
• Spasticity in multiple sclerosis: Associations with impairments and overall quality of life.

  2016cited by this paper
• A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis

  2016cited by this paper
• Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study

  2016cited by this paper
• MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY

  2015cited by this paper
• Anticholinergics for urinary symptoms in multiple sclerosis.

  2015cited by this paper
• Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice

  2014cited by this paper
• Spasticity in patients with multiple sclerosis – clinical characteristics, treatment and quality of life

  2014cited by this paper
• Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

  2014cited by this paper
• Clinical Understanding of Spasticity: Implications for Practice

  2014cited by this paper
• Spasticity in multiple sclerosis: results of a patient survey

  2013cited by this paper
• Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study

  2013cited by this paper
• Natural history of multiple sclerosis symptoms.

  2013cited by this paper
• [Consensus document on spasticity in patients with multiple sclerosis. Grupo de Enfermedades Desmielinizantes de la Sociedad Española de Neurología].

  2013cited by this paper
• A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis

  2011cited by this paper
• A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

  2010cited by this paper
• Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.

  2008cited by this paper
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

  2008cited by this paper
• A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.

  2006cited by this paper
• Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

  2004cited by this paper

• Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis

  2026cites this paper
• Nabiximols improves sleep architecture in multiple sclerosis: A prospective polysomnographic study.

  2026cites this paper
• A proof-of-concept study on the effectiveness of botulinum toxin on spasticity plus syndrome in multiple sclerosis

  2026cites this paper
• Epigenetic and Mitochondrial Metabolic Dysfunction in Multiple Sclerosis: A Review of Herbal Drug Approaches and Current Clinical Trials

  2025cites this paper
• Acute cannabidiol (CBD), tetrahydrocannabinol (THC) and their mixture (THC:CBD) exert differential effects on brain activity and blood flow in rats: A translational neuroimaging study.

  2025cites this paper
• Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis

  2024cites this paper
• Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures

  2024cites this paper
• Effect of nabiximols oromucosal spray (Sativex®) on symptoms associated with multiple sclerosis-related spasticity: a case series

  2024cites this paper
• Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain

  2024cites this paper
• Clinical outcome analysis of patients with multiple sclerosis - Analysis from the UK Medical Cannabis Registry.

  2024cites this paper
• Anti-Cancer and Anti-Proliferative Potential of Cannabidiol: A Cellular and Molecular Perspective

  2024cites this paper
• Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple Sclerosis

  2024cites this paper
• Nabiximols (NBX) suppresses tremor in a rat Harmaline model of essential tremor.

  2024cites this paper
• Cannabinoids for spasticity in patients with multiple sclerosis: A systematic review and meta-analysis

  2024cites this paper
• Retrospective study on the presence of spasticity-plus syndrome in the advanced practice nurse’s office in multiple sclerosis

  2023cites this paper
• Medical Cannabis: A Review from the American Society of Pain and Neuroscience

  2023cites this paper
• Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria

  2023cites this paper
• Estudio retrospectivo sobre la presencia del síndrome de spasticity-plus en la consulta de la enfermera de práctica avanzada en esclerosis múltiple

  2023cites this paper
• Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study.

  2023cites this paper
• A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’

  2022cites this paper
• Spasticity following brain and spinal cord injury: assessment and treatment

  2022cites this paper
• Clinical insights on the spasticity-plus syndrome in multiple sclerosis

  2022influential citation